BOSTON, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (“Compass”) (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that the Company will participate in the following investor events during the month of September. Details are as follows: Citi’s 2025 Biopharma Back to School Conference Location: Boston, MADate: Tuesday, September 2, 2025 Cantor Global Healthcare Confe ...

VANCOUVER, British Columbia, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Vortex Energy Corp. (CSE: VRTX) (OTC: VTECF) (FSE: AA3) (“Vortex” or the “Company”) is pleased to announce that its field crews have mobilized back to the Robinsons River Salt Project in Newfoundland and Labrador to begin the recollection of Ambient Noise Tomography (“ANT”) sensors. This marks a milestone in the ANT survey program, as the sensors have now completed their required data collection period. The retrieval process will allow the Compa ...

Core Perspective - Genmab A/S announced that the U.S. FDA has granted Breakthrough Therapy Designation to rinatabart sesutecan (Rina-S) for treating adult patients with recurrent or progressive endometrial cancer who have experienced disease progression after prior treatments [2][7] Company Overview - Genmab is an international biotechnology company focused on developing innovative antibody therapeutics, with a vision to transform the lives of patients with cancer and other serious diseases by 2030 [10][11] Product Development - Rina-S is an investigational antibody-drug conjugate targeting folate receptor alpha (FRα) and is currently undergoing late-stage development, including ongoing Phase 1/2 and Phase 3 trials for various cancers [4][8] - The Breakthrough Therapy Designation is supported by results from the Phase 1/2 RAINFOL™-01 trial, which showed encouraging responses in heavily pretreated endometrial cancer patients [3][7] Clinical Trial Insights - The RAINFOL™-01 trial is an open-label, multicenter study designed to evaluate the safety and efficacy of Rina-S in solid tumors expressing FRα, with multiple cohorts focusing on different cancer types [5][8] - The trial's B2 cohort included 64 patients with advanced or recurrent endometrial cancer who had progressed after anti-PD-(L)1 and platinum-based chemotherapy [3][6] Market Context - Endometrial cancer is the second most prevalent gynecologic cancer globally, with increasing incidence and limited treatment options for advanced cases, highlighting the need for innovative therapies like Rina-S [6][8]

Company Overview - Esperion Therapeutics, Inc. is a commercial stage biopharmaceutical company focused on developing new medicines for unmet patient needs, particularly in cardiovascular disease [3] - The company has developed the only FDA-approved oral, once-daily, non-statin medications for patients with elevated low-density lipoprotein cholesterol (LDL-C) [3] - Esperion's medications are supported by the CLEAR Cardiovascular Outcomes Trial, which involved nearly 14,000 patients [3] Upcoming Events - Esperion will participate in the Cantor Global Healthcare Conference in New York on September 3, 2025, at 9:45 a.m. ET [1] - The company will also attend the H.C. Wainwright 27th Annual Global Investment Conference in New York on September 8, 2025, at 2:00 p.m. ET [1] Webcast Information - Live webcasts of the events can be accessed on the investor and media section of the Esperion website [2] - Replay of the webcasts will be available approximately two hours after the events and archived for about 90 days [2] Strategic Focus - Esperion is advancing its pre-clinical pipeline and focusing on developing ATP citrate lyase inhibitors (ACLYi) [3][4] - The company aims to leverage new insights into the structure and function of ACLYi for rational drug design, targeting the development of highly potent and specific inhibitors [3]

- ASP Isotopes will host an investor access event on Tuesday, August 26, 2025 at its Pretoria facilities for approximately 30 South African investors. - ASP Isotopes expects to have a secondary listing on the Johannesburg Stock Exchange (JSE) and its common stock is expected to commence trading on the JSE on Wednesday, August 27, 2025. - ASP Isotopes has shipped its first samples of enriched Silicon-28 to a US-based customer and expects to complete the enrichment of the first samples of Ytterbium 176 during ...

Company advancing U.S. commercialization with FDA-approved ketamine and rare disorder NDA filingsTORONTO, Aug. 26, 2025 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the "Company" or "PharmaTher") (OTCQB: PHRRF) (CSE: PHRM), a specialty pharmaceutical company focused on unlocking the pharmaceutical potential of ketamine, is pleased to provide a corporate update highlighting commercial readiness for ketamine (KETARx™) and an ambitious regulatory program aimed at advancing KETARx™ for rare disorders. Fabio Ch ...

Total Staking Rewards Increased to 1,799 ETH as of August 24, 2025; Approximately $200 Million in Cash Available for Additional ETH Acquisitions MINNEAPOLIS, MN, Aug. 26, 2025 (GLOBE NEWSWIRE) -- SharpLink Gaming, Inc. (Nasdaq: SBET) (“SharpLink” or the “Company”), one of the world’s largest corporate holders of Ether (“ETH”) and prominent industry advocate of Ethereum adoption, today issued its update on the Company’s ETH purchases for the period Monday, August 18, 2025 through Sunday, August 24, 2025; and ...

Core Insights - The article highlights a shift in consumer shopping behavior, with 85% of consumers starting summer shopping earlier, indicating a new peak season for businesses and tax professionals [1][3] - The traditional peak shopping season has expanded beyond the holidays, with summer travel, back-to-school shopping, and Halloween contributing to increased consumer demand [2] - Automated tax technology is essential for businesses to manage the complexities of tax compliance during these new peak shopping periods [4][5] Consumer Behavior - 53% of consumers are purchasing items earlier due to concerns about price increases and product availability [3] - 55% of consumers prefer a blended shopping experience, shopping both in-store and online [7] - 69% of consumers take advantage of summer holiday weekend sales, which can challenge retailers in maintaining compliance [7] Business Implications - Businesses must prepare for peak shopping periods by implementing automated tax solutions to ensure compliance and accuracy [4][5] - The need for precision in tax operations is paramount, as 76% of consumers buy summer clothing and accessories, and 71% shop for summer hobbies [4] - Automated tax platforms help reduce errors and ensure accurate tax treatment across various sales channels [9][14] Tax Compliance Challenges - Seasonal shopping spikes introduce complex tax challenges due to varying tax rates and rules across jurisdictions [6] - Different fulfillment methods can trigger varying tax rules, complicating compliance for businesses [9] - Automated tax solutions are crucial for handling high volumes of transactions without disruption [14] Company Overview - Vertex Inc. is a global provider of indirect tax solutions, helping businesses manage tax compliance and operational efficiency [11] - The company offers tailored solutions for various industries, focusing on major lines of indirect tax [11]

Core Insights - Commerce has launched a headless ecommerce experience on the BigCommerce platform in collaboration with Metrolinx, enhancing passenger checkout experience and operational efficiencies [1][2] - The new platform supports product management, bundling, pricing, and promotions, providing a secure and scalable solution for Metrolinx [2][3] - The integration with Stripe payment gateway allows for future expansion of payment methods, improving the overall customer journey [2][6] Company and Industry Overview - Commerce operates as an open, AI-driven commerce ecosystem, empowering businesses to innovate and grow by unlocking data potential [7] - BigCommerce, as a subsidiary of Commerce, offers a composable architecture that enhances ecommerce capabilities, including advanced security and compliance features [6][7] - The partnership between Commerce, EPAM, and Metrolinx demonstrates the effectiveness of collaboration in delivering innovative solutions and improving operational efficiency [5][6]

Core Insights - Nasus Pharma Ltd. has successfully listed on the New York Stock Exchange and celebrated this milestone by ringing the Closing Bell on August 25, 2025, highlighting its commitment to transforming emergency medicine through innovative intranasal therapies [1][2][3] Company Overview - Nasus Pharma is a clinical-stage pharmaceutical company focused on developing intranasal powder products aimed at treating acute medical conditions, particularly severe allergic reactions and anaphylaxis [4] - The company's lead product candidate, NS002, is an intranasal powder formulation of Epinephrine, designed as a needle-free alternative to traditional Epinephrine autoinjectors [4] Technology and Innovation - The proprietary powder-based intranasal (PBI) technology developed by Nasus Pharma is intended for rapid and reliable drug delivery, utilizing the nasal cavity's vascular network for quick absorption [4] - The PBI formulation employs uniform spherical powder particles to ensure broad dispersion and potentially faster absorption compared to liquid-based nasal products [4] Leadership and Vision - The CEO of Nasus Pharma, Dan Teleman, emphasized the company's dedication to innovation and its mission to develop life-saving treatments that are easy to use and accessible during emergencies [3]